Company: DVAX
Filing Date: 2025-04-03
Form Type: PREC14A
Source: 0000930413-25-001153
Chunk: 58

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-03
Form: PREC14A
Chunk 58
---

following the effectiveness of the Declassification Restatement.

Impact if the Declassification Restatement is Not Adopted

If our stockholders do not approve this Proposal 4, we will continue
to have a classified Board, with directors serving staggered, three-year terms.

Vote Required

Approval of this proposal requires the affirmative vote of the holders
of sixty-six and two-thirds percent (66-2/3%) of the shares of common stock issued and outstanding as of the Record Date. Abstentions
and broker non-votes have the same effect as negative votes.

<div align='center'>THE BOARD OF DIRECTORS RECOMMENDS
A VOTE “FOR” PROPOSAL 4.</div>

| 41 |

<div align='center'>EXECUTIVE OFFICERS</div>

The following table sets forth certain information with respect to
our executive officers as of April 14, 2025:

| Name                 |     | Age | Position                                                                                              |
| Ryan Spencer(1)(2)   |     |  47 | Chief Executive Officer and Director(2)                                                               |
| Kelly MacDonald(2)   |     |  41 | Senior Vice President, Chief Financial Officer(2)                                                     |
| David F. Novack      |     |  63 | President and Chief Operating Officer                                                                 |
| John L. Slebir       |     |  59 | Senior Vice President, General Counsel                                                                |
| Robert Janssen, M.D. |     |  71 | Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs |

| (1) | Please see “Proposal 1 – Election of Directors” in this proxy statement for more information                                         
 about Mr. Spencer.                                                                                                                   |
| (2) | On March 29, 2024, we appointed Ryan Spencer to serve in a temporary capacity as interim Chief Financial Officer while Ms. MacDonald 
 was on maternity leave. Ms. MacDonald resumed her role as Chief Financial Officer on August 1, 2024, upon her return from maternity  
 leave.                                                                                                                               |

Kelly MacDonald – Senior Vice President, Chief Financial Officer

Ms. MacDonald joined Dynavax in March 2021 as Senior Vice President,
Chief Financial Officer, and Principal Financial Officer, and Ms. MacDonald was appointed as Principal Accounting Officer in February
2025. Prior to Dynavax, Ms. MacDonald worked at Ironwood Pharmaceuticals, Inc. from 2013 to 2021 where she held roles of increasing